redefining first-in-class drug discovery

NEXOGENE BIOTECH

Pioneering small-molecule therapies for neurodegeneration, cancer, and aging transforming bold science into real patient impact.

we are
nexogene

We develop first-in-class small-molecule therapies by pairing computational design with experimental validation. Our focus is neurodegeneration, oncology, and aging delivering assets pharma can evaluate quickly and scale with confidence.

Innovation

Innovation where others stop

We take on the hardest problems neurodegeneration, mitochondrial dysfunction, and genetic regulation using bold science and fast translation to cut risk and bring hope to patients sooner.

From Science to Therapies

By uniting precision chemistry and biology, we crack the undruggable advancing first-in-class therapies that reach patients faster and give partners a clearer path to scale.

what sets us apart

Why Us ?

Leading first-in-class discovery with science, speed, and strategic focus.

Scientific Rigor

We combine computational chemistry with experimental validation to develop drug candidates that show strong preclinical promise.

Novel Target

Focused on first-in-class opportunities where pharma has struggled and patients still wait.

Efficient Execution

A lean, milestone-driven model that delivers synthesis, in vivo, and proof-of-concept data faster and more cost-effectively.

Partner Ready

Structured data, clear protocols, and pharma-grade documentation make our programs easy to evaluate and advance.

Our portfolio

Pipeline

A focused portfolio of first-in-class small-molecule therapies.

Nexogene Pipeline

Let’s Connect

© 2026 Nexogene Biotech. All rights reserved.